Aktie A3C8YB BIOPLUS ACQUISITION CORP.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen BioPlus Acquisition Corp. Nasdaq

Aktien

A3C8YB

KYG112171098

BIOSU

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
BioPlus Acquisition Corp.(NasdaqGM:BIOS) dropped from NASDAQ Composite Index
BioPlus Acquisition, Avertix Medical Terminate Business Combination Deal
BioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to Liquidate
Avertix Medical, Inc. terminated the acquisition of BioPlus Acquisition Corp. from BioPlus Sponsor LLC, Highbridge Capital Management, LLC, Saba Capital Management, L.P., Cantor Fitzgerald & Co, Investment Arm and others in a reverse merger transaction.
Heart & Rhythm Institute of Trinity and Avertix Announce Partnership to Improve Cardiac Care and Patient Monitoring
BioPlus Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Renown Cardiologist and Professor Ian T. Meredith, MD to Join Avertix Medical’s Board of Directors
Avertix’s Guardian™ System, First and Only FDA-Approved Implantable Heart Attack Detection and Warning System, Now Available at AdventHealth Orlando
BIOPLUS ACQUISITION CORP. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
BioPlus Acquisition Corp. announced that it has received $1.5 million in funding
BIOPLUS ACQUISITION CORP. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
BioPlus Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023
BIOPLUS ACQUISITION CORP. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Avertix Medical, Inc. entered into a definitive merger agreement to acquire BioPlus Acquisition Corp. from BioPlus Sponsor LLC, Highbridge Capital Management, LLC, Saba Capital Management, L.P., Cantor Fitzgerald & Co, Investment Arm and others for approximately $170 million in a reverse merger transaction.
BIOPLUS ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
BioPlus Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022
BioPlus Acquisition Corp. Auditor Raises 'Going Concern' Doubt
BIOPLUS ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
BioPlus Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
BIOPLUS ACQUISITION CORP. : Other Events (form 8-K)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DFBM Aktie
  4. A3C8YB Aktie
  5. Nachrichten BioPlus Acquisition Corp.
  6. Andere Sprachen